What's The Business/Financial Case For Building Capacity?
Source: Outsourced Pharma
We asked our three, non-financial biopharma panelists to make their business/financial case for or against internal build out at emerging companies, particularly for organizations pursuing advanced therapies.
Interested in the complete presentation? Click here.
This website uses cookies to ensure you get the best experience on our website. Learn more